Scimplify Secures $25M from Hitachi Ventures: Navigating High-Tech Chemical Manufacturing and GST Realities

Bengaluru-headquartered B2B manufacturing startup Scimplify has secured $25 million in a funding round spearheaded by Hitachi Ventures. The capital injection underscores a structural pivot in institutional capital toward industrial deep tech, contract research, and domestic chemical synthesis. Including this latest round, Scimplify has amassed approximately $80 million in total funding, achieving a post-money valuation of $249 million as of July, based on data tracked by Tracxn.

The financing round attracted a cohort of strategic commercial partners alongside institutional backers. Global industrial players such as Henkel, Teknor Apex, and a Japanese chemical enterprise participated as strategic corporate investors that also operate as Scimplify’s commercial clients. Existing investors—including Accel, 3one4 Capital, Bertelsmann India Investments, and Omnivore—also backed the round. As Indian contract development and manufacturing organizations (CDMOs) gain traction globally, such corporate capital inflows reflect wider institutional shifts in corporate finance, moving away from purely consumer-facing internet platforms toward asset-heavy, tech-enabled manufacturing.

Rapid Revenue Growth and Global Supply Realignment

Founded in 2023 by Sachin Santhosh, Salil Srivastava, Dheeraj Dhingra, and Hersh Manek, Scimplify manages an integrated pipeline spanning early chemical discovery to commercial-scale synthesis. According to corporate filings accessed via Tracxn, the founders retain a collective 29.8% equity stake, while 3one4 Capital holds 15.2% and Accel holds 13.7%.

Financial statements lodged with the Ministry of Corporate Affairs reveal an 11-fold surge in operational scale: revenue expanded from ₹18.3 crore in FY24 to ₹204.3 crore in FY25. Parallel to this top-line escalation, operational losses widened from ₹1.9 crore to ₹25.4 crore over the same timeframe, reflecting aggressive outlays in infrastructure and workforce expansion. International markets currently generate 50% of the firm’s revenues—up from 20% a year prior—with management targeting a 70% overseas contribution by the end of next year.

The firm plans to allocate the fresh capital toward expanding research laboratories in Bengaluru and Hyderabad, scaling its proprietary AI-driven platform SciNode, and entering American and European markets. In the United States, Scimplify plans to establish processing infrastructure and domestic manufacturing partnerships centered on rare earths, critical metals, and ultra-high-purity inputs for batteries and semiconductors—critical nodes in the expanding high-tech semiconductor supply chains.

Indirect Tax Implications: Export Structuring and Zero-Rated Supplies

From an indirect taxation perspective, Scimplify’s accelerating cross-border pivot alters its Goods and Services Tax (GST) risk and compliance profile. Under Indian GST law, outbound cross-border sales of speciality chemicals qualify as “zero-rated supplies.” Exporters face two statutory avenues: exporting under a Letter of Undertaking (LUT) without the payment of Integrated GST (IGST) and seeking a refund of accumulated unutilized Input Tax Credit (ITC), or paying IGST upfront and claiming a subsequent rebate.

For high-growth chemical manufacturers with rapid working capital turnover, maintaining smooth cash flows requires precision in processing LUT-based refund applications under Section 54 of the Central GST Act. Chemical synthesis relies heavily on input chemicals, specialized reagents, industrial gases, and lab testing consumables, many of which attract GST rates of 18% or 28%. When raw inputs are acquired at standard rates while the final output is exported tax-free, enterprises generate significant ITC balances. Any mismatch between invoice data filed by suppliers in GSTR-1 and the manufacturer’s GSTR-2B can trap substantial liquidity, directly affecting operational margins.

R&D Capital Expenditure, SciNode, and Inverted Duty Dynamics

Scimplify’s allocation of capital toward laboratory infrastructure in Bengaluru and Hyderabad introduces additional tax and accounting complexities. High-tech analytical equipment—such as spectrometry units, chromatography systems, and automated synthesis reactors—involves substantial upfront capital expenditure. Maximizing ITC claims on capital goods demands meticulous documentation to ensure that equipment qualifies as eligible input tax under Section 16, avoiding exclusions under Section 17(5).

Simultaneously, the continuous development of the in-house SciNode platform, an artificial intelligence engine designed to oversee synthesis pathways, involves cross-functional costs. When software design, computational resources, and outsourced cloud capabilities are procured domestically or imported, companies must navigate the reverse charge mechanism (RCM) under GST. Proper classification between “supply of goods” and “supply of services” is paramount, particularly when software deliverables are bundled with laboratory analytical reports for domestic clients such as Dr. Reddy’s, Mankind Pharma, Coromandel, or BASF.

Furthermore, catering to domestic buyers alongside international clients can trigger an inverted duty structure. If certain domestic agricultural or intermediate chemical classifications enjoy concessional GST rates relative to higher-rated precursor compounds, manufacturers must navigate statutory refund formulas, which restrict refund eligibility primarily to input goods rather than input services or capital equipment.

Strategic Corporate Customers and Related-Party Scrutiny

A distinctive feature of Scimplify’s model is that several strategic equity backers—including Henkel, Teknor Apex, and Hitachi affiliates—are simultaneously active purchasing clients. This dual relationship introduces tax considerations under both GST valuation rules and direct tax transfer pricing frameworks.

Under GST statutory provisions, transactions between “related persons” or distinct persons are subject to enhanced valuation scrutiny. Where equity ownership or strategic board control establishes an affiliated status, supplies of custom compounds, contract development services, or proprietary chemical batches cannot simply rely on transaction value. The company must establish that all supplies conform strictly to open market benchmarks, backed by comprehensive cost-construction methodologies under Rule 30 or Rule 31 of the CGST Rules, to withstand audit inquiries from tax authorities.

The Broader Macroeconomic and Industrial Backdrop

The rapid expansion of Scimplify reflects a broader resurgence in domestic production capacity. According to Venture Intelligence, venture and private equity funding into Indian manufacturing startups surged from $164 million in 2020 to $1.92 billion in 2026. This trend aligns with policy efforts to establish resilient electronics component manufacturing ecosystems and specialized material fabrication within India.

As specialty chemical synthesis transitions from fragmented, unorganized operations into institutionalized platforms serving sectors from aerospace to pharmaceuticals, regulatory compliance evolves in parallel. Successfully executing a global CDMO strategy depends not merely on advanced laboratory chemistry, but equally on managing cross-border supply chain logistics, customs documentation, and robust indirect tax governance.

Frequently Asked Questions